CAJ | 학술논문

目的：探讨埃克替尼治疗33例非小细胞肺癌（ non small cell lung cancer，NSCLC ）患者的疗效及安全性。方法对33例患者的临床特点、治疗效果、不良反应及生存时间进行了回顾性分析。所有患者均口服埃克替尼125 mg，3次/d，直到病变进展或不能耐受。结果 KPS评分升高率为21．2％（7例），埃克替尼总有效率24．2％，疾病控制率87．9％。中位生存时间10．2个月，1年生存率42．4％。脑转移患者的有效率明显高于无脑转移的患者。腺癌、无脑转移、KPS评分高的患者的生存时间优于其他病理类型、有脑转移、KPS评分低的患者。埃克替尼的不良反应主要表现为轻度皮疹、皮肤干燥、腹泻。结论埃克替尼治疗晚期NSCLC具有较好的疗效及安全性。
목적：탐토애극체니치료33례비소세포폐암（ non small cell lung cancer，NSCLC ）환자적료효급안전성。방법대33례환자적림상특점、치료효과、불량반응급생존시간진행료회고성분석。소유환자균구복애극체니125 mg，3차/d，직도병변진전혹불능내수。결과 KPS평분승고솔위21．2％（7례），애극체니총유효솔24．2％，질병공제솔87．9％。중위생존시간10．2개월，1년생존솔42．4％。뇌전이환자적유효솔명현고우무뇌전이적환자。선암、무뇌전이、KPS평분고적환자적생존시간우우기타병리류형、유뇌전이、KPS평분저적환자。애극체니적불량반응주요표현위경도피진、피부간조、복사。결론애극체니치료만기NSCLC구유교호적료효급안전성。
Objective To evaluate the clinical efficacy and tolerability of Icotinib in advanced NSCLC patients .Methods The clinical characteristics , response to treatment , adverse reaction and survival were retrospectively reviewed in thirty -three advanced NSCLC patients .All these patients received Icotinib 125 mg three times a day until disease progression or unacceptable toxicity .Results Seven cases (21.2%) had improved KPS score .Overall response rate and disease control rate (DCR) of Icotinib were 24.2%and 87.9%, respectively.The median survival time was 10.2 months.One year sur-vival rate was 42.4%.The response rate to Icotinib was significantly higher in patients with brain metastasis than patients without brain metastasis .The overall survival times were significantly longer in patients of adenocarcinoma , without brain metastasis and high KPS score than patients of other pathological type , with brain metastasis and low KPS score .Rash, di-arrhea and xerosis cutis were the most common adverse effects ( AEs) , but usually were mild .Conclusion Icotinib has bet-ter curative effect and insignificant adverse reaction in the treatment of NSCLC .